141 related articles for article (PubMed ID: 10602891)
1. Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009.
Holcombe RF; Jacobson J; Dakhil SR; Stewart RM; Betzing KS; Kannan K; Macdonald JS
Cancer Immunol Immunother; 1999 Dec; 48(9):533-9. PubMed ID: 10602891
[TBL] [Abstract][Full Text] [Related]
2. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
[TBL] [Abstract][Full Text] [Related]
3. Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil.
Holcombe RF; Stewart RM; Betzing KW; Kannan K
Cancer Immunol Immunother; 1994 Jun; 38(6):394-8. PubMed ID: 7515770
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Staib L; Link KH; Beger HG;
J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for colon cancer in the new millenium.
Rao S; Cunningham D
Scand J Surg; 2003; 92(1):57-64. PubMed ID: 12705552
[TBL] [Abstract][Full Text] [Related]
6. Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Estes NC; Giri S; Fabian C
Am Surg; 1996 Jul; 62(7):546-49; discussion 549-50. PubMed ID: 8651549
[TBL] [Abstract][Full Text] [Related]
7. North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
O'Connell MJ
Semin Oncol; 2001 Feb; 28(1 Suppl 1):4-8. PubMed ID: 11273589
[TBL] [Abstract][Full Text] [Related]
8. Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
Van Cutsem E; Costa F
JAMA; 2005 Dec; 294(21):2758-60. PubMed ID: 16333012
[No Abstract] [Full Text] [Related]
9. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.
Jessup JM; Stewart A; Greene FL; Minsky BD
JAMA; 2005 Dec; 294(21):2703-11. PubMed ID: 16333005
[TBL] [Abstract][Full Text] [Related]
10. The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone.
Cascinu S; Catalano V; Piga A; Mattioli R; Marcellini M; Pancotti A; Bascioni R; Torresi U; Silva RR; Pieroni V; Giorgi F; Catalano G; Cellerino R
Cancer Invest; 2003; 21(5):701-7. PubMed ID: 14628428
[TBL] [Abstract][Full Text] [Related]
11. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH; Veeder MH; Mailliard JA
Ann Intern Med; 1995 Mar; 122(5):321-6. PubMed ID: 7847642
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Taal BG; Van Tinteren H; Zoetmulder FA;
Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Lancet; 2000 May; 355(9215):1588-96. PubMed ID: 10821362
[TBL] [Abstract][Full Text] [Related]
16. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
17. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints.
Holcombe RF; Milovanovic T; Stewart RM; Brodhag TM
Cancer Detect Prev; 2001; 25(2):183-91. PubMed ID: 11341354
[TBL] [Abstract][Full Text] [Related]
18. [The adjuvant chemotherapy of obstructive colonic cancer].
Matviĭchuk BO
Lik Sprava; 1998; (7):105-7. PubMed ID: 10050474
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
; Gray R; Barnwell J; McConkey C; Hills RK; Williams NS; Kerr DJ
Lancet; 2007 Dec; 370(9604):2020-9. PubMed ID: 18083404
[TBL] [Abstract][Full Text] [Related]
20. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
